Incyte Corp. Stock
Incyte Corp. Stock
Incyte Corp. gained 0.140% compared to yesterday.
We see a rather positive sentiment for Incyte Corp. with 12 Buy predictions and 2 Sell predictions.
With a target price of 78 € there is a hugely positive potential of 56.19% for Incyte Corp. compared to the current price of 49.94 €.
Our community identified positive and negative aspects for Incyte Corp. stock for the coming years. 1 users see the criterium "EBIT growth" as a plus for the Incyte Corp. stock. On the other hand our users think that "Customer and product portfolio" could be a problem in the future.
Pros and Cons of Incyte Corp. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Incyte Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Incyte Corp. | 0.140% | 3.417% | -2.193% | -18.876% | -11.984% | -29.583% | -32.027% |
| Exact Sciences | 1.820% | 4.930% | -14.192% | 0.139% | -15.832% | -44.565% | -38.396% |
| Regeneron Pharmaceuticals Inc. | 0.550% | 7.756% | 1.276% | 22.311% | 11.498% | 119.637% | 195.121% |
| Amgen Inc. | 10.960% | 14.603% | 14.150% | 39.306% | 10.975% | 42.148% | 83.108% |
Comments
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at TD Cowen from $88.00 to $80.00. They now have a "buy" rating on the stock.
Show more
Ratings data for INCY provided by MarketBeat
Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $83.00 price target on the stock, down previously from $84.00.
Show more
Ratings data for INCY provided by MarketBeat
Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $92.00 to $84.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for INCY provided by MarketBeat